Literature DB >> 29340905

Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.

Lidija Todorović1, Boban Stanojević2, Vesna Mandušić2, Nina Petrović2,3, Vladan Živaljević4,5, Ivan Paunović4,5, Aleksandar Diklić4,5, Vladimir Saenko6, Shunichi Yamashita6.   

Abstract

A growing body of evidence suggests a role of the von Hippel-Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR. We explored the correlation between them and their association with clinicopathological parameters. The results revealed that both VHL and miR-92a were either up- or downregulated in PTCs compared to corresponding non-tumor tissues. On univariate analysis, lower VHL levels were significantly associated with extrathyroid spread (P = 0.022) and capsular invasion (P = 0.032). Multivariate analysis confirmed the association of low VHL with extrathyroid spread (OR 0.246, 95% CI 0.069-0.872, P = 0.038). Higher miR-92a among PTC tissues associated with the presence of nodal metastases (univariate analysis: P = 0.012; multivariate: OR 4.703, 95% CI 1.109-19.938, P = 0.036). A negative correlation between VHL and miR-92a was observed in a subgroup of PTCs having vascular invasion (P = 0.033, r = - 0.673). The data here reported demonstrate that the expression of both VHL and miR-92a is deregulated in PTC tissues and that in some PTCs they may have opposite roles. These roles, as well as their diagnostic and/or prognostic utility, remain to be clarified.

Entities:  

Keywords:  Aggressive features; Expression; PTC; Thyroid cancer; VHL; miR-92a

Mesh:

Substances:

Year:  2018        PMID: 29340905     DOI: 10.1007/s12032-017-1066-3

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  44 in total

1.  Reduced expression of von Hippel-Lindau protein correlates with decreased apoptosis and high chondrosarcoma grade.

Authors:  Changbao Chen; Hua Zhou; Xiaoguang Liu; Zhongjun Liu; Qingjun Ma
Journal:  J Bone Joint Surg Am       Date:  2011-10-05       Impact factor: 5.284

Review 2.  miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma.

Authors:  Weiqi Tan; Yang Li; Seng-Gee Lim; Theresa M C Tan
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

3.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

4.  Expression pattern of the von Hippel-Lindau protein in human tissues.

Authors:  M Los; G H Jansen; W G Kaelin; C J Lips; G H Blijham; E E Voest
Journal:  Lab Invest       Date:  1996-08       Impact factor: 5.662

5.  The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms.

Authors:  Isabella Manni; Simona Artuso; Silvia Careccia; Maria Giulia Rizzo; Renato Baserga; Giulia Piaggio; Ada Sacchi
Journal:  FASEB J       Date:  2009-07-16       Impact factor: 5.191

Review 6.  BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Authors:  Mingzhao Xing
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

7.  Expression profiling of selected microRNA signatures in plasma and tissues of Saudi colorectal cancer patients by qPCR.

Authors:  Yazeed A Al-Sheikh; Hazem K Ghneim; Khalil I Softa; Abdulrahman A Al-Jobran; Omar Al-Obeed; Mansoor A V Mohamed; Maha Abdulla; Mourad A M Aboul-Soud
Journal:  Oncol Lett       Date:  2015-12-31       Impact factor: 2.967

8.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

Authors:  Gabriella Pellegriti; Francesco Frasca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Cancer Epidemiol       Date:  2013-05-07

9.  MicroRNA-92 regulates cervical tumorigenesis and its expression is upregulated by human papillomavirus-16 E6 in cervical cancer cells.

Authors:  Yu Yu; Yao Zhang; Shulan Zhang
Journal:  Oncol Lett       Date:  2013-06-17       Impact factor: 2.967

10.  Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma.

Authors:  Boban Stanojevic; Vladimir Saenko; Lidija Todorovic; Nina Petrovic; Dragan Nikolic; Vladan Zivaljevic; Ivan Paunovic; Masahiro Nakashima; Shunichi Yamashita; Radan Dzodic
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

View more
  4 in total

1.  MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer.

Authors:  Sha Xiao; Ming Zhang; Chang Liu; Deling Wang
Journal:  Mol Genet Genomics       Date:  2018-05-11       Impact factor: 3.291

2.  Prognostic biomarkers for predicting papillary thyroid carcinoma patients at high risk using nine genes of apoptotic pathway.

Authors:  Chakit Arora; Dilraj Kaur; Leimarembi Devi Naorem; Gajendra P S Raghava
Journal:  PLoS One       Date:  2021-11-12       Impact factor: 3.240

Review 3.  MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.

Authors:  Maria Papaioannou; Angeliki G Chorti; Anthoula Chatzikyriakidou; Kleanthis Giannoulis; Sohail Bakkar; Theodosios S Papavramidis
Journal:  Front Oncol       Date:  2022-02-03       Impact factor: 6.244

4.  The Association of the BRAF-V600E Mutation with the Expression of the Molecular Markers in the Primary Tumor and Metastatic Tissue in Papillary Thyroid Cancer.

Authors:  Liudmila V Spirina; Svetlana Yu Chizhevskaya; Irina V Kovaleva; Irina V Kondakova
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.